AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Alnylam Pharmaceuticals Surges to Top 319 in Trading Volume with $268 Million Day
Generated by AI AgentAinvest Volume Radar
Tuesday, Jun 24, 2025 8:00 pm ET1min read
On June 24, 2025,
(ALNY) saw a significant surge in trading volume, reaching $268 million, marking a 70.28% increase from the previous day. This placed among the top 319 stocks by trading volume for the day. The stock price also rose by 3.66%, continuing its upward trend for the second consecutive day, with a total increase of 4.81% over the past two days.Alnylam Pharmaceuticals has recently announced that the U.S. Food and Drug Administration (FDA) has approved its investigational drug, patisiran, for the treatment of hereditary transthyretin amyloidosis (hATTR). This approval marks a significant milestone for the company, as it is the first and only RNA interference (RNAi) therapeutic approved for this rare and debilitating disease. The approval is based on positive results from the APOLLO Phase 3 study, which demonstrated a significant reduction in disease progression and improvement in quality of life for patients treated with patisiran.
In addition to the FDA approval, Alnylam has also announced that it has entered into a strategic collaboration with a leading biopharmaceutical company to develop and commercialize a new class of RNAi therapeutics for the treatment of cardiovascular diseases. This collaboration is expected to accelerate the development of innovative therapies for patients suffering from these diseases and further strengthen Alnylam's position as a leader in the RNAi therapeutics space.
Furthermore, Alnylam has reported positive interim results from its ongoing Phase 2 study of ALN-AS1, an investigational RNAi therapeutic for the treatment of alpha-1 antitrypsin deficiency (AATD). The results showed a significant reduction in serum alpha-1 antitrypsin (AAT) levels and improvement in lung function for patients treated with ALN-AS1. These findings support the potential of ALN-AS1 as a novel therapeutic option for patients with AATD, a rare genetic disorder that can lead to severe lung and liver disease.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet